[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644042":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Breast cancer patients with local recurrence after radical surgery",null,"This cohort includes female patients aged ≥18 with pathologically confirmed isolated local breast cancer recurrence after radical surgery (breast-conserving surgery or total mastectomy) and no distant metastasis, who can tolerate anti-tumor therapy and complete long-term follow-up. This is a non-interventional prospective cohort without experimental interventions; all patients receive standard salvage therapies per national breast cancer guidelines and hospital MDT rules. Treatments of interest are salvage reoperation, postoperative radiotherapy, chemotherapy, endocrine therapy and anti-HER2 targeted therapy for recurrent lesions. Researchers collect full baseline, primary tumor, surgery and recurrence treatment data, and conduct ≥3 years of follow-up to record PFS, OS, secondary local recurrence, distant metastasis and adverse events.",[13],"Other: Individualized therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Individualized therapy","This is a non-interventional prospective cohort study. No experimental treatments are provided by researchers. All therapeutic interventions are standard salvage therapies formulated by the hospital MDT team following official breast cancer guidelines, including salvage reoperation, postoperative radiotherapy, chemotherapy, endocrine therapy and anti-HER2 targeted therapy. The study only retrospectively collects and compares routine clinical treatment data to explore their associations with patients' survival outcomes, and will not adjust or allocate any treatment plans for participants.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"WenBin Zhou, Ph.D","CONTACT","025-68308161","zhouwenbin@njmu.edu.cn",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100644042","prospective-cohort-study-of-local-recurrence-after-radical-breast-cancer-resection-100644042",false,"NCT07668362","Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection","Clinicopathological Characteristics and Prognosis of Local Recurrence After Radical Mastectomy for Breast Cancer: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Patients with a prior history of breast-conserving surgery or total mastectomy, with postoperative pathological diagnosis of invasive breast carcinoma or ductal carcinoma in situ (DCIS);\n2. Pathologically confirmed isolated local recurrence of breast cancer after primary surgery, without evidence of distant metastasis;\n3. Aged ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and eligible to receive reoperation and subsequent anti-tumor therapy;\n4. Voluntarily participate in this study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of concurrent distant metastasis at the time of breast cancer local recurrence;\n2. Severe dysfunction or failure of vital organs (cardiac, hepatic, renal, etc.) that contraindicates reoperation or systemic anti-tumor treatment;\n3. Inability to complete scheduled long-term follow-up as required by the study.","ALL","18 Years",{"count":37,"type":38},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to analyze clinicopathological characteristics and identify independent prognostic risk factors, as well as compare treatment outcomes in female patients aged ≥18 years with pathologically confirmed local recurrence of breast cancer after radical surgery (breast-conserving surgery or total mastectomy) without distant metastasis. The main questions it aims to answer are:\n\nWhat clinical and pathological factors independently affect progression-free survival (PFS) and overall survival (OS) of breast cancer patients with postoperative local recurrence? Do clinical features and long-term prognosis differ between patients with local recurrence after breast-conserving surgery and those after total mastectomy? Can we identify optimal individualized treatment regimens and suitable populations for re-breast-conserving surgery and postoperative radiotherapy after R0 resection?\n\nParticipants will:\n\nProvide complete baseline demographic, initial clinicopathological, primary surgical and adjuvant treatment data, local recurrence lesion characteristics and post-recurrence treatment information via standardized case report forms; Undergo routine clinical examinations, imaging reviews and pathological rechecks as standard clinical practice; Receive standardized follow-up for at least 3 years through outpatient visits supplemented by telephone\u002FWeChat contact to record disease progression, secondary local recurrence, distant metastasis, all-cause death and treatment adverse events.",[42],"Breast Cancer",[44,45,46],"Breast cancer","Local recurrence","Prospective cohort study","NOT_YET_RECRUITING","2026-06-22",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":38},"2026-07-20",{"date":55,"type":38},"2036-12-30",{"name":5,"class":6}]